Ryan Faucette

Ryan Faucette has over 18 years of experience in the biotechnology and pharmaceutical industries. Ryan began their career in 2003 as a Research Assistant at the Joslin Diabetes Center, where they assisted with research on Type 2 Diabetes. In 2005, they joined SmartCells, Inc. as a Research Associate. In 2006, they joined Wyeth as a Scientist I in Assay Development, where their primary responsibilities included development and qualification of pharmacokinetic and anti-product assays using ELISA and BioVeris formats. In 2007, they joined Acceleron Pharma as a Senior Research Associate in BioAnalytical Development, where their primary responsibilities included development, qualification, and validation of pharmacokinetic, anti-drug antibody, and potency assays using ELISA and MSD. In 2011, they joined Dyax as a Staff Scientist I, Scientist, and Senior Research Associate. In 2016, they joined Shire as a Scientist. In 2017, they joined Scholar Rock as a Senior Scientist and Scientist. In 2021, they joined Keros Therapeutics as a Senior Scientist. Most recently, they joined Q32 Bio Inc. as a Principal Scientist in 2022.

Ryan Faucette attended Bates College from 1998 to 2002, where they earned a Bachelor of Science degree in Biology.